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Alzheimer's diseaseThe human BCL6 gene encodes a transcriptional repressor that is crucial for germinal center B cell development
and T follicular helper cell differentiation. It is involved in the pathogenesis of certain human lymphomas. In an
effort to identify targets of BCL6 repression, we used a previously described cell system inwhich BCL6 repressive
effects are inhibited, followed by subtractive hybridization, and identiﬁed the integral membrane 2B gene
(ITM2B, formerly BRI2) as a potential target. Here we show that BCL6 can bind to its preferential consensus bind-
ing site within the ﬁrst intron of ITM2B and represses its transcription. Knockdown of endogenous BCL6 in a
human B cell lymphoma line increases ITM2B expression. Further, there is an inverse relationship between the
expression levels of BCL6 and ITM2B proteins in 16 human B- and T-cell lymphomas studied by immunohisto-
chemistry. Both the BCL6 and ITM2B proteins are expressed ubiquitously. Similar to some other targets of
BCL6, a short form of the ITM2B protein generated by alternative splicing induces apoptosis in hematopoietic
cell lines. Molecular alterations in the ITM2B gene are associated with two neurodegenerative diseases, Familial
British and Familial Danish dementia. ITM2B dysfunction also may be relevant for the development of
Alzheimer's disease. Our data conﬁrm ITM2B as a target of BCL6 repression in lymphoma. A further understanding
of the genes that function as regulators of the ITM2B protein may provide insights for the development of new
molecular tools not only for targeted lymphoma therapy but also for the treatment of these dementias.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The BCL6 nuclear zinc ﬁnger protein is encoded by a gene located on
chromosome 3, band q27, and functions as a transcriptional repressor
[1–4]. It has long been known to play an important role in the pathogen-
esis of diffuse large B cell lymphomas, and, more recently, its additional
role in T-cell biology has been appreciated [5,6]. BCL6 has been called a
“master regulator” of germinal center formation and is believed to re-
press the transcription of hundreds of proteins [7]. In a study of germi-
nal center B cells and diffuse large cell lymphomas, it was found to bind
to the promoters of about 3,000 genes (enhancer and intronic elements
were not studied). Less frequently, BCL6 has been implicated in the reg-
ulation of the growth of other cancers, e.g., colorectal and breast cancer,CCD, The University of Chicago,
USA. Tel.: +1 773 702 1439;
. Baron),
.bsd.uchicago.edu (J.M. Baron).as well as in the control of other disease processes, e.g., myasthenia
gravis [8–10].
In an effort to identify BCL6 target genes, we previously developed a
dominant-negative cell system in which the BCL6 repressive effects are
inhibited, enabling the detection of genes that are ordinarily repressed.
By subtractive hybridization, we selectively ampliﬁed differentially
expressed sequences, thus detecting upregulated messages [11]. With
the use of this methodology, we now describe the identiﬁcation of the
integralmembrane 2B gene (ITM2B, formerly called BRI2) as a novel tar-
get of BCL6 repression.
Like the BCL6 protein, the ITM2B protein is expressed ubiquitously
[12]. A short form of the ITM2B protein, which is generated by alterna-
tive splicing, has been shown to induce apoptosis in hematopoietic cell
lines [13], a function that is similar to someother targets of BCL6 [11,14].
However, ITM2B has not been studied in the context of human lympho-
mas. Interestingly, alterations in the ITM2B gene are associatedwith two
neurodegenerative diseases, Familial British dementia (FBD) and Famil-
ial Danish dementia (FDD), and data have been presented indicating
that aberrant ITM2B function also may play a role in the development
of Alzheimer's disease (AD) [15–20]. Therefore, an understanding of
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implications for new therapeutic tools.2. Materials and methods
2.1. Differential expression by Northern blotting
Preparation of constructs, cDNA subtraction, and ampliﬁcation of
differentially expressed sequences have been described previously
[11]. Brieﬂy, through the use of a cell system in which the BCL6 repres-
sive effects were inhibited, we identiﬁed upregulated genes that are or-
dinarily its targets of repression. We converted the BCL6 zinc ﬁngers
(BCL6ZF), which bind DNA but lack repressive effects, into a transcrip-
tional activator as described and used this construct to compete with
wild-type endogenous BCL6 in a cell line (BJAB, an Epstein–Barr virus-
negative Burkitt lymphoma cell line) expressing BCL6 at high levels
[11]. The cells were transiently transfected with this construct or the
vector in which it had been cloned. Subtractive hybridization was
performed, and the inserts of the cDNA clones obtained after PCR
were sequenced. Potential targets of the BCL6 repressive effects were
32P-labeled and hybridized to Northern blots prepared from BJAB cells
that had been transfected with the BCL6ZF construct or the vector. The
blots were washed under stringent conditions, exposed to ﬁlm, then
the probes were stripped, and the blots were rehybridized with a 32P-
labeled human β-actin cDNA control probe (Clontech Laboratories,
Inc, Mountain View, CA), washed under stringent conditions, and
reautoradiographed. Quantitation of relative band intensity was
normalized to β-actin by scanning densitometry.2.2. Consensus binding site
To clone the sequences surrounding the preferential consensus
binding site for BCL6, 0.697 kb of human genomic DNA was ampliﬁed
by PCR (forward primer, 5′- GGACACTGCTGTAGCATATTGG-3′; reverse
primer, 5′-CTTTCATTGTGAAGCACAGCTC-3′); 1 μl of the PCR product
was blunted and ligated to 50 μg of the pJET 1.2/Blunt Cloning Vector
(Thermo Scientiﬁc, Waltham, MA) per the manufacturer's guidelines.
The appropriate insert was isolated from this vector with BglII restric-
tion enzyme digests and ligated to the BglII site of the pGL3 basic
luciferase reporter vector (Promega, Madison, WI) (PGL3ITM2B).2.3. ChIP assay
Two ChIP assays were performed with an EZ-ChIP™ Chromatin Im-
munoprecipitation Kit (#17-371, EMD Millipore Corp, Billerica, MA).
BJAB cells (Burkitt lymphoma line rich in endogenous BCL6, described
above), 4.7 × 106 per sample, were cross-linked with 1% formaldehyde
for 5min at room temperature. The reactionwas terminatedwith an ex-
cess of glycine. Cross-linked chromatin was sonicated to ~200–1000 bp
with aMicroson™XL 2000 sonicator (Qsonica, LLC, Newtown, CT); cells
were vortexed then sonicated four times on ice, on average, at 9W, 7W,
and 5W twice, for 10 s each, respectively, with a 50 s cooling period on
ice between sonications, followed by immunoprecipitation with anti-
bodies to BCL6 (sc-858 X, Santa Cruz Biotechnology, Dallas, TX) and
anti-rabbit IgG as a negative control. ChIP DNA was ampliﬁed by PCR.
One set of primers (described in the Consensus Binding Site section)
ampliﬁed the BCL6 consensus site in the ﬁrst intron of the ITM2B gene,
and another set of primers ampliﬁed a coding region of ITM2B, which
did not contain any putative BCL6 binding sites. These primers ampliﬁed
100 bpwithin the second exon of ITM2B: forward primer, 5′-GGTACCAG
TTGGCCAAAGAA-3′; reverse primer, 5′-TTTGTACAAGTATGCTCCTCCT
AGA-3′. Bands were detected on 0.8% and 0.9% agarose gels,
respectively.2.4. Transfection assays/functional analysis
NIH3T3 cells (murine ﬁbroblasts with minimal expression of both
endogenous BCL6 [21] and ITM2B [22], which we have previously
used for similar studies [4,23], were grown under standard conditions
and plated at 1.5 to 4 × 105 cells per well in a six-well dish. They were
transfected the next day by calcium phosphate DNA-coprecipitation or
by TurboFect™ Transfection Reagent (Thermo Scientiﬁc) with
PGL3ITM2B (0.6 to 0.65 μg)—a construct containing the exact BCL6 con-
sensus binding site identiﬁed in the ﬁrst intron of the ITM2B gene, and
either full-length BCL6 cDNA (1.25 to 1.46 μg) subcloned in the pCGN
expression vector (pCGNBCL6) or an equivalent amount of a truncated
BCL6 expression construct (control), also subcloned in the pCGN vector.
Wehave used this truncated construct in prior studies as a control [4,23]
because it lacks the zinc ﬁnger DNA-binding region of BCL6 and, there-
fore, cannot bind DNA. A CMV-driven β-galactosidase expression con-
struct was cotransfected. Cells were harvested at 47.5 h to 70 h.
Luciferase levels were normalized for transfection efﬁciency by using
the values of β-galactosidase assays as previously described [4].
Relative luciferase activity was deﬁned as the luciferase levels ob-
tained with the BCL6 construct divided by the luciferase levels obtained
with the truncated control. A paired t test was used to evaluatewhether
themean relative luciferase activity of the ITM2B consensus binding site
in the cells transfectedwith BCL6 vs. those transfectedwith the truncat-
ed control from three independent experiments (triplicate wells in
each) was signiﬁcantly different from 1.2.5. Transfection of BCL6 siRNAs and Western blotting
BJAB cells were transfected with human BCL6 siGENOME
SMARTpool reagent or CONTROL nontargeting siRNA 1 (Dharmacon,
LaFayette, CO) by electroporation as described previously [23].
Whole cell extracts were prepared from the transfected cells and sub-
jected to Western blotting as described. The antibodies used included
rabbit polyclonal antibodies to BCL6 (sc-858 or sc-368, Santa Cruz Bio-
technology, Santa Cruz, CA), a validated afﬁnity-isolated Prestige anti-
body to ITM2B produced in rabbit (Sigma-Aldrich Co. LLC, Saint Louis,
MO, #HPA029292), and afﬁnity-isolated actin antibody produced in
rabbit (#A2066, Sigma-Aldrich). The membranes were washed and in-
cubated with anti-rabbit IgG (Fc), alkaline phosphatase conjugate
(Promega, Madison, WI), then washed again. Protein bands were de-
tected with Western Blue Stabilized Substrate for Alkaline Phosphatase
(Promega).
Calculations of relative band intensity on four Western blots were
normalized to the intensity ofβ-actin expression by scanningdensitom-
etry. The paired t test was used to compare BCL6 and ITM2B protein
levels, respectively, in the siRNA BCL6-transfected cells with the corre-
sponding control cells.2.6. Immunohistochemistry
Human parafﬁn-embedded lymphoma blocks were retrieved from
the Surgical Pathology archives under an institutional review board-
approved protocol. In each case, the sections that are stained with the
different antibodies are from the same tissue block, but they are not nec-
essarily consecutive sections. BCL6 stainingwas performed as described
previously [24] with mousemonoclonal anti-human BCL6 (clone LN22;
Novocastra). Staining for ITM2B was performed overnight at 4 °C with
an afﬁnity-isolated Prestige antibody produced in rabbit (Sigma-
Aldrich, Saint Louis, MO, #HPA029292) that was diluted 1:20–1:25.
Antigen–antibody binding was detected with DAB chromogen, and
tissues were counterstained with hematoxylin. Images were taken
with a BX41 microscope (Olympus), DP72 digital camera, and cellSens
Standard imaging software (Olympus).
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3.1. Subtractive hybridization and ampliﬁcation of differentially expressed
cDNAs in BJAB cells transfected with the BCL6 zinc ﬁngers or vector control
followed by nucleotide sequencing
We used the BCL6 zinc ﬁngers (BCL6ZF), which bind DNA but lack
the BCL6 repressive effects, to compete with endogenous BCL6 in BJAB
cells (Epstein–Barr virus-negative Burkitt lymphoma cell line) [11].
Cells also were transfected with the vector used for cloning, and sub-
tractive hybridizationwas performed. Primary and secondary PCR prod-
ucts of the experimental subtracted sample revealed differentially
expressed bands on an ethidium bromide-stained 2% agarose gel
when comparedwith the unsubtracted control. As previously described
[11], the ﬁnding that sequences from two of the clones analyzed were
identical to overlapping regions of BCL6ZF (indicating identiﬁcation of
BCL6ZF mRNA that had been overexpressed in the study cells) implied
that subtractive hybridization had been successful. The sequences
from another clone matched the human integral membrane protein
2B (ITM2B) gene (formerly called BRI2).
3.2. Northern blotting conﬁrms differential expression of ITM2B
Four Northern blots were prepared from the total RNA of BJAB cells
transiently transfected with the BCL6ZF study construct (S lane) or vec-
tor control (C lane) as previously described [11], and they were hybrid-
izedwith the cDNA fragment of ITM2B obtained from cDNA subtraction/
ampliﬁcation. A representative Northern blot is shown in Fig. 1A. The
expected two transcripts [12]were noted (1.7 kb and 1.2 kb, respective-
ly). Relative band intensity normalized to β-actin by scanning densi-
tometry showed that, for the four blots, differential expression of
ITM2B (S lane) as compared with the control (C) was, by paired t test,
mean ± SEM = 1.65 ± 0.11 for the upper band (p b 0.01), rangeFig. 1.Northern blotting conﬁrms differential expression of ITM2B. (A) Autoradiograph of
a Northern blot prepared from total RNA of BJAB cells transiently transfected with an ex-
pression (study) construct (S) containing the BCL6 zinc ﬁngers or the vector into which
the S construct was cloned (control, C). Top panel: Hybridization with a cDNA fragment
of ITM2B obtained from subtractive hybridization; its ~1.7 and ~1.2 kb transcripts are
noted. Bottom panel: The blot was stripped and rehybridized with a human β-actin
probe. Differential expression of ITM2B normalized to β-actin for this blot is 2-fold for
the upper band and 3-fold for the lower band. (B) For the four Northern blots performed,
densitometry indicates that differential expression of ITM2B (S lane) as compared with
the control (C) is, by paired t test, mean ± SEM, 1.65 ± 0.11 for the upper band (p b
0.01), range 1.45- to 1.95-fold; 2.33 ± 0.54 for the lower band (p = 0.09), range 1.27-
to 3.46-fold; and 1.98 ± 0.30 for the averaged bands (p 0.05), range 1.43- to 2.53-fold.1.45- to 1.95-fold; 2.33 ± 0.54 for the lower band (p = 0.09), range
1.27- to 3.46-fold; and 1.98 ± 0.30 for the averaged bands (p 0.05),
range 1.43- to 2.53-fold (Fig. 1B).
3.3. The BCL6 protein binds to the high-afﬁnity BCL6 binding site in the ﬁrst
intron of ITM2B
We identiﬁed an exact match to the consensus binding site for BCL6
([A/T]TC[C/T][A/T][A/C]GA) [25] within the ﬁrst intron of the ITM2B
gene (TTCCTAGA, nt 48,811,973–48,811,980). This sequence was pres-
ent in both of the protein-encoding transcripts of the gene. Tiling
ChIP-on-chip experiments have shown that BCL6 preferentially local-
izes to this element [25].
Two ChIP assays were performed and showed that in a B cell
lymphoma line, endogenous BCL6 was bound to the region in the ﬁrst
intron of the ITM2B gene containing the BCL6 consensus binding site
because DNA from this region was enriched in chromatin
immunoprecipitated with anti-BCL6 (Fig. 2A, lane 5). This genomic re-
gion was not enriched in material immunoprecipitated with anti-
rabbit IgG (Fig. 2A, lane 1),while a bandof the correct sizewas observedFig. 2. The BCL6 protein binds to ITM2B in BJAB cells (ChIP assay). (A) The ﬁrst intronic re-
gion of ITM2B containing the BCL6 consensus binding site (0.697 kb). BCL6 is bound to the
region of the ﬁrst intron of ITM2B containing the putative BCL6 binding site (arrow) be-
cause DNA from this area is enriched in chromatin immunoprecipitated with anti-BCL6
(lane 5). Rabbit antibody, lane 1 (control) does not enrich this genomic region. The posi-
tive (+) control (lane 6) is genomic DNA ampliﬁed with the same primers. Lane 3 is
1 Kb Plus DNA Ladder (Invitrogen™, Life Technologies, Grand Island, NY), and lane 4 is
input. All of the lanes are from the samegel. (B) ITM2B coding region (0.1 kb, arrow). Bind-
ing of BCL6 to the coding region of ITM2B (lane 1) is not detected, as there is no putative
binding site in this region. Input (lane 3) and the positive (+) control (genomic DNA,
lane 4) ampliﬁed with the same primers (within the second exon of ITM2B) show the ex-
pected 100 bp product (arrow). Lane 2 is 100 bp DNA Ladder (New Engl. Biolabs, Ipswich,
MA).
Fig. 4. siRNA duplexes speciﬁcally targeting BCL6 lead to an increase in endogenous ITM2B
expression. (A) RepresentativeWestern blot showing BCL6, β-actin (as previously report-
ed [23]), and ITM2B protein expression at 47 h in BJAB cells transiently transfected with
siRNA duplexes [C, control siRNA; S, study (BCL6) siRNA]. The ITM2B pro-peptide (pro-
ITM2B) is detected at ~50 kDa, and mature ITM2B (lacking the pro-peptide) is noted at
a somewhat lower molecular weight [26]. (B) The graph depicts the relative protein ex-
pression of BCL6 and ITM2B in C and S cells after normalization for β-actin expression.
(Left) BCL6 protein expression (mean ± SEM: control siRNA, 0.93 ± 0.22; BCL6 siRNA,
0.60 ± 0.17; p= 0.01). (Right) ITM2B protein expression (mean ± SEM: control siRNA,
0.51 ± 0.17; BCL6 siRNA, 0.93 ± 0.26; p= 0.01).
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binding of BCL6was detected to the coding region of ITM2B, which does
not contain a putative binding site (Fig. 2B, lane 1), while a band in the
correct location was observed with input (lane 3) and the positive con-
trol (genomic DNA, lane 4).
3.4. The BCL6 protein represses transcription from the BCL6 consensus bind-
ing site in the ﬁrst intron of ITM2B
Transient transfections performed in NIH3T3 cells revealed that rel-
ative luciferase levels, depicted in Fig. 3 from three independent exper-
iments, indicated signiﬁcant repression (p 0.0001) from the BCL6
consensus binding site in the ﬁrst intron of ITM2B by the full-length
BCL6 protein (mean±SD=0.31±0.16) as comparedwith a truncated
control that cannot bind DNA (for comparison, the absolute value of the
control was set at 1). These studies show that BCL6 directly represses
ITM2B and provide evidence for transcriptional regulation of ITM2B by
BCL6.
3.5. Knockdown of the BCL6 protein increases endogenous ITM2B
expression
Transient transfection of siRNA duplexes targeting endogenous BCL6
in BJAB cells led to knockdown of BCL6 protein levels that could be de-
tected by 24 h and persisted until at least 47 h (Fig. 4A, conﬁrming suf-
ﬁcient knockdown of BCL6 with the siRNA, as demonstrated previously
[23]). Datawere analyzed from four independent experiments. The pro-
peptide of ITM2Bwasdetected at amolecularmass of ~50 kDa in all four
experiments, andmature ITM2B (lacking the pro-peptide)was detected
at a lower molecular weight [26]. Relative band intensities on Western
blots were normalized to β-actin, which was used to determine theFig. 3. The BCL6 protein represses transcription from sequences containing the BCL6 con-
sensus binding site in the ﬁrst intron of ITM2B. Relative luciferase levels in NIH3T3 cells
show signiﬁcant repression (p 0.0001) of transcription (mean ± SD= 0.31 ± 0.16) by
the full-length BCL6 protein from sequences encompassing the BCL6 consensus binding
site in the ﬁrst intron of the ITM2B gene as compared with a truncated control lacking
the BCL6 zinc ﬁngers, which are needed to bind DNA. The data were normalized with re-
sults for the control designated as 1.amount of protein loaded. Between 42 and 47 h, overall knockdown of
the BCL6 proteinwas 35.2% (range, 29% to 56%;mean± SEM for control
siRNA was 0.93 ± 0.22 as compared with 0.60 ± 0.17 for cells
transfected with BCL6 siRNA, p= 0.01). Higher levels of ITM2B protein
were noted at the same time points (overall, a 1.8-fold increase in en-
dogenous ITM2B in the siRNA-BCL6-transfected cells as compared
with control cells, range 1.64 to 4.9-fold, mean ± SEM for control
siRNA 0.51 ± 0.17 as compared with 0.93 ± 0.26 for cells transfected
with BCL6 siRNA, p = 0.01, Fig. 4B). These observations conﬁrm that
an increase in endogenous ITM2B expression is a direct effect of BCL6
knockdown.
3.6. Reciprocal relationship between BCL6 and ITM2B protein expression in
human lymphomas
The relationship between BCL6 and ITM2B protein expression was
studied in 16 human lymphomas (10 B cells, 6 T cells) by immunohisto-
chemical staining (Fig. 5). B cell lymphomas: nine of the B cell lympho-
mas were positive for BCL6 and negative for ITM2B (representative
example, Fig. 5, panel 1). The tenth B cell tumor was variably positive
or negative for BCL6; the BCL6 positive areas were negative for ITM2B
and vice-versa. T-cell lymphomas: four T-cell lymphomas were positive
for BCL6 and negative for ITM2B (representative example Fig. 5, panel
2). Two T-cell lymphomas were negative for BCL6 and positive for
ITM2B (Fig. 5, panel 3).
4. Discussion
The human ITM2B gene (formerly called BRI2) has been mapped to
chromosome13q14.3.Wild-type ITM2B is a type II transmembranepro-
tein containing 266 amino acids. Northern blotting identiﬁes two tran-
scripts, 1200 nt and 1700 nt long, respectively, originating from
poly(A) signals at positions 1114 and1593 [12]. The apparentmolecular
mass of the ITM2B protein (42–44 kDa) is higher than predicted from
the number and composition of amino acids, suggesting that it is
Fig. 5. Immunohistochemistry of representative human lymphomas depicting an inverse
relationship between BCL6 and ITM2B expression. In each case, the H&E stain reveals ef-
facement of normal tissue architecture with replacement by malignant cells. Panels 1
and 2 depict B- and T-cell lymphomas, respectively, that are BCL6 positive (brown nuclear
staining) and ITM2B negative. Panel 3 shows a BCL6-negative T-cell lymphoma that is
ITM2B positive (brown, granular cytoplasmic staining). The bar (lowest right panel) indi-
cates 20 μm.
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and is processed by furin and ADAM10 (a disintegrin and metallopro-
teinase domain 10) as well as other proteases in a fashion similar to
Notch to release secreted fragments [26]. The pro-peptide of ITM2B
can be detected at a molecular mass of ~50 kDa on Western blots, and
the mature variant lacking the pro-peptide is noted at a slightly lower
molecular weight [26]. Alternative splicing generates a long and short
form of ITM2B. Interestingly, the short form induces apoptosis indepen-
dently of p53 in hematopoietic cell lines [13], a function that is similar to
that of some other targets of BCL6, e.g., PDCD2 [28].
BCL6 encodes a POZ/zincﬁnger transcriptional repressor, which reg-
ulates gene expression by interactions with co-repressors that recruit
histone deacetylases and induce epigenetic remodeling and heterochro-
matin formation [29,30]. BCL6 expression is not limited to B cells; BCL6
also contributes to the normal function of T-cell subsets [5,6], macro-
phages [31], progenitor cells during normal hematopoiesis, and to the
function of cancer stem cells in myeloid leukemia [30]. Further, BCL6
has been found to be involved in interactions with other genes that af-
fect neural functions such as G protein signaling in neuron-like cells
[32] and differentiation of the cerebral cortex in a mouse model [33].
The BCL6 and ITM2B proteins are both expressed in many tissues,
not only in lymphoid and hematopoietic cells [13,29] but also in the
brain [12,34,35]. In human brain and mouse brain, ITM2B has been
found to be expressed in olfactory neurons, the cerebral cortex, hippo-
campus, and cerebellum. In the mouse, BCL6 expression is found in
these regions as well [36–40]. In humans, although BCL6 is expressed
in the brain [34], to our knowledge, its regional distribution has not
been characterized. Since ITM2B and BCL6 have a similar regional ex-
pression pattern in the mouse, at least, experiments to study the possi-
ble colocalization and regulation of ITM2B by BCL6 in the human brain
and in neuron-derived cells would be of great interest. Additionally,
testing the effects of BCL6 in a three-dimensional humanneural cell cul-
ture model of Alzheimer's disease such as that recently published by
Choi et al. [41] would be very exciting.
Workingwith a B lymphoma cell line, we have presented the follow-
ing observations in support of the concept that the ITM2B gene is a tar-
get of BCL6 repression: (a) subtractive hybridization in this cell line, inwhich BCL6 repressive effects were inhibited, followed by Northern
blotting, revealed differential expression of ITM2B; (b) ChIP assays
showed that BCL6 binds to the high-afﬁnity consensus binding site
identiﬁed in the ﬁrst intron of the ITM2B gene; (c) in transient transfec-
tion assays the full-length BCL6 protein caused signiﬁcant repression
(3-fold) from the BCL6 consensus binding site in the ﬁrst intron of
ITM2B as compared with a truncated control lacking the BCL6 zinc ﬁn-
gers that cannot bind DNA; (d) knockdown of BCL6 by siRNA duplexes
led to a signiﬁcant increase in endogenous ITM2B protein; and (e) im-
munohistochemical staining revealed a reciprocal relationship between
BCL6 and ITM2B protein expression in B- and T-cell human lymphomas.
The short form of the ITM2B protein appears to play a role in induc-
tion of apoptosis [13]. Through repression of speciﬁc target genes, it is
very likely that BCL6 inhibits apoptosis [11,14,23,28]. Thus, the deregu-
lation of BCL6, as is known to be associated with lymphomagenesis,
likely leads to perturbation of apoptosis events, perhaps resulting in ab-
normal growth of cells. Only about 50% of B cell lymphomas can be
curedwith current therapies; T-cell lymphomas are evenmore resistant
to treatment than B cell tumors, and most patients die from these neo-
plasms. The inhibition or upregulation of speciﬁc targets could permit
the selection of patientswith B- or T-cell lymphomaswhomight beneﬁt
most (personalized therapy) and reduce the unwanted side effects of
more global immunosuppressive and cytotoxic treatments.
No approved speciﬁc molecular targeted treatment is available for
FBD, FDD or AD, whichmay share commonmolecular pathways leading
to dementia [35]. Familial dementias are caused by mutations in the
gene that encodes the amyloid precursor protein (APP) [42] and in
genes that regulate the processing of APP [43], which include ITM2B;
the ITM2B protein binds to APP and inhibits its processing [16,18,44].
Fotinopoulou et al. [44] reported an interaction between the amyloid
precursor protein (APP) and ITM2B, which led to a reduction in APP se-
cretion as well as amyloid β (Aβ) peptides. Their data suggested that
ITM2B inhibits the activity of α-secretase. Matsuda et al. demonstrated
that maturation and transport of ITM2B along the secretory pathway is
essential for generating an inhibitor of the processing of the APP. These
data establish ITM2B as a potentially important molecular target for an
anti-amyloid therapy in AD [16–18,44].
Peng et al. [45] suggested a model for how the processing of ITM2B
and APP are related—these authors found that recombinant human
ITM2B, residues 90–236, binds to ABri23 (themain component of amy-
loid deposits in FBD) aswell as to Aβ1–40 (which is cleaved from the N-
terminal extracellular part of APP), inhibiting its aggregation and ﬁbril
formation. They found that the binding of ABRi23 to ITM2B(90–236)
is stronger than that of Aβ1–40, which blocks interactions between
ITM2B and APP. Proteolytic release of the ABRi23 peptide results in
making the ITM2B pocket available for binding to the Aβ region of
APP. Tamayev et al. indicated that reducing β-cleavage of the APP is
an appropriate approach for treating human dementias [19]. In a
mouse model, Tamayev et al. showed that memory deﬁcits due to the
FBD ITM2Bmutation are due to loss of ITM2B function rather than am-
yloidosis [20]. Similarly, in a mouse knock-in model of FDD, loss of
ITM2B function, not the amyloid cascade, resulted in synaptic andmem-
ory deﬁcits [46]. Consistent with this ﬁnding, the levels of several
amyloid-β protein precursor (AβPP) metabolites, including Aβ, were
found to be increased in the brain from a patientwith FDD [47]. Further,
Tamayev et al. reported that APP heterozygosity prevents memory and
synaptic dysfunctions in FDD knock-in mice, suggesting that FDD path-
ogenesis may be due to APP and/or toxic APP metabolites [48]. APP
haploinsufﬁciency also prevented memory deﬁcits in a murine knock-
in model of FBD [49].
In addition, Tamayev and D'Adamio [50] reported that as ITM2B
binds to APP and inhibits APP cleavage by secretases, processing of
APP is increased in FDD due to the loss of ITM2B. Processing of APP by
β-secretase results in the products amino-terminal-soluble APPβ
(sAPPβ) and β-carboxyl-terminal (β-CTF); γ-secretase processing of
the latter product yields Aβ, which is considered the main cause of
747B.W. Baron et al. / Biochimica et Biophysica Acta 1852 (2015) 742–748AD, but inhibition of γ-secretase did not ameliorate the synaptic/mem-
ory deﬁcits of FDD knock-in mice. Thus, the authors [50] suggested that
APP and ITM2B interact, that APP mediates FDD neuropathology, and
that sAPPβ and/or β-CTF (not Aβ) are the cause of dementia. Lombino
et al. [43] showed that mutation of a single residue of APP, the intracel-
lular amino acid Thr668, which prevents phosphorylation at this residue,
can prevent memory and synaptic plasticity deﬁcits in the knock-in
mouse model of FDD. APPPThr668 is enriched in patients with AD [51],
suggesting a pathogenic role for phosphorylation at this site. Because
this mutation does not appear to alter essential functions of APP during
development [52], it has been suggested [43] that targeting the role of
Thr668, and perhaps its phosphorylation,mayoffer a safe therapeutic ap-
proach to dementias.
Of additional interest are the recentﬁndings byDel Campo et al. [15],
indicating that the ITM2B-containing BRICHOS-domain is increased up
to 3-fold in the hippocampus of patientswith early stages of AD as com-
pared with controls, and loss of ITM2B function in AD is supported by
the decreased presence of ITM2B-amyloid precursor protein complexes
in the hippocampus of these patients. Thus, a further understanding of
the genes, such as BCL6, that function as regulators of the ITM2B protein
may provide insights for the development of new, speciﬁc molecular
therapies that could beneﬁt patients who will die from these diseases.
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